Elan has announced encouraging results from trials of its Antegren treatment for Crohn's disease.
Antegren has been co-developed by Elan and Biogen and has passed third phase trials investigating the treatment of response in Crohn's disease after 10 weeks.
Dr Lars Ekman, head of R&D at Elan, said the company was "extremely encouraged" by the findings and that it was committed to the further development and evaluation of the drug.
Elan will discuss the data with regulatory authorities in the United States and Europe and determine the next phase of development before licensing.
